SBRT治疗早期肺癌:活检证实和经验治疗病变的结果

Pub Date : 2018-04-17 eCollection Date: 2018-03-01 DOI:10.2217/lmt-2018-0006

Rodney E Wegner, Nissar Ahmed, Shaakir Hasan, Lana Y Schumacher, Matthew Van Deusen, Athanasios Colonias

{"title":"SBRT治疗早期肺癌:活检证实和经验治疗病变的结果","authors":"Rodney E Wegner, Nissar Ahmed, Shaakir Hasan, Lana Y Schumacher, Matthew Van Deusen, Athanasios Colonias","doi":"10.2217/lmt-2018-0006","DOIUrl":null,"url":null,"abstract":"Aim: Herein, we compare outcomes in patients treated with lung stereotactic body radiotherapy (SBRT) with and without tissue confirmation.Methods: We reviewed 196 patients that underwent lung SBRT for presumed (100 patients) or proven non-small-cell lung cancer (96 patients) over a 10-year period and compared outcomes.Results: A total of 196 patients with a median age of 76 underwent lung SBRT to a median dose of 48 Gy in four fractions. Median follow up was 17 months. Local control and overall survival at 3 years was 94 and 58% for the entire group. There was no difference in overall survival, local control, regional control or distant control between the cohorts.Conclusion: SBRT is a safe and effective treatment for patients with non-small-cell lung cancer that are medically inoperable with comparable results in empirically treated patients.","PeriodicalId":0,"journal":{"name":"","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2018-04-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.2217/lmt-2018-0006","citationCount":"17","resultStr":"{\"title\":\"SBRT for early stage lung cancer: outcomes from biopsy-proven and empirically treated lesions.\",\"authors\":\"Rodney E Wegner, Nissar Ahmed, Shaakir Hasan, Lana Y Schumacher, Matthew Van Deusen, Athanasios Colonias\",\"doi\":\"10.2217/lmt-2018-0006\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Aim: Herein, we compare outcomes in patients treated with lung stereotactic body radiotherapy (SBRT) with and without tissue confirmation.Methods: We reviewed 196 patients that underwent lung SBRT for presumed (100 patients) or proven non-small-cell lung cancer (96 patients) over a 10-year period and compared outcomes.Results: A total of 196 patients with a median age of 76 underwent lung SBRT to a median dose of 48 Gy in four fractions. Median follow up was 17 months. Local control and overall survival at 3 years was 94 and 58% for the entire group. There was no difference in overall survival, local control, regional control or distant control between the cohorts.Conclusion: SBRT is a safe and effective treatment for patients with non-small-cell lung cancer that are medically inoperable with comparable results in empirically treated patients.\",\"PeriodicalId\":0,\"journal\":{\"name\":\"\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":0.0,\"publicationDate\":\"2018-04-17\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://sci-hub-pdf.com/10.2217/lmt-2018-0006\",\"citationCount\":\"17\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.2217/lmt-2018-0006\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2018/3/1 0:00:00\",\"PubModel\":\"eCollection\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.2217/lmt-2018-0006","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2018/3/1 0:00:00","PubModel":"eCollection","JCR":"","JCRName":"","Score":null,"Total":0}

引用次数: 17

摘要

目的:在此，我们比较了有和没有组织确认的肺立体定向放射治疗(SBRT)患者的结果。方法:我们回顾了196例在10年期间接受肺SBRT治疗的患者，这些患者被推测为(100例)或证实为非小细胞肺癌(96例)，并比较了结果。结果:共有196名中位年龄为76岁的患者接受了肺SBRT治疗，中位剂量为48 Gy，分四次进行。中位随访时间为17个月。局部控制率和3年总生存率分别为94%和58%。在总体生存率、局部控制、区域控制或远程控制方面，各组之间没有差异。结论:对于医学上不能手术的非小细胞肺癌患者，SBRT是一种安全有效的治疗方法，与经验治疗的患者效果相当。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

摘要图片

查看原文

微信好友朋友圈 QQ好友复制链接

SBRT for early stage lung cancer: outcomes from biopsy-proven and empirically treated lesions.

Aim: Herein, we compare outcomes in patients treated with lung stereotactic body radiotherapy (SBRT) with and without tissue confirmation.

Methods: We reviewed 196 patients that underwent lung SBRT for presumed (100 patients) or proven non-small-cell lung cancer (96 patients) over a 10-year period and compared outcomes.

Results: A total of 196 patients with a median age of 76 underwent lung SBRT to a median dose of 48 Gy in four fractions. Median follow up was 17 months. Local control and overall survival at 3 years was 94 and 58% for the entire group. There was no difference in overall survival, local control, regional control or distant control between the cohorts.

Conclusion: SBRT is a safe and effective treatment for patients with non-small-cell lung cancer that are medically inoperable with comparable results in empirically treated patients.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助